Key Points {#FPar1}
==========

Several new drugs have recently been approved for the treatment of patients with relapsed/refractory multiple myelomaThe therapeutic regimen of choice for patients with relapsed/refractory multiple myeloma depends on disease- and patient-related factors, as well as on type of prior treatment

Introduction {#Sec1}
============

Over the past two decades, the median survival of patients with multiple myeloma (MM) has significantly improved, from 3 to 4 years to approximately 7--8 years \[[@CR1]\], mainly due to the application of high-dose conventional therapy with autologous stem-cell transplantation (HDT-ASCT) as a routine procedure for transplant-eligible MM patients; significant improvements in supportive care strategies; and the introduction and wide-spread use of the immunomodulatory drugs (IMiDs) thalidomide and lenalidomide and the proteasome inhibitor (PI) bortezomib \[[@CR2]\]. These novel agents nowadays represent the backbone of many current standard-of-care therapies for MM patients, both at diagnosis and in the relapse setting.

However, MM remains an incurable malignancy with most patients experiencing relapse and requiring additional therapy. In particular, the prognosis of MM patients who have received at least three prior lines of therapy, who have become double refractory to IMiDs (lenalidomide or pomalidomide) and PIs (bortezomib or carfilzomib) and who have been exposed to an alkylating agent, is very poor with an event-free survival and overall survival of only 5 and 13 months, respectively \[[@CR3]\].

New insights into biology of the disease have resulted in the development of additional novel agents targeting specific pathways involved in tumor cell growth and survival. Due to their effectiveness and tolerability, some of these agents have received fast-track approval and have now moved to phase III and IV clinical studies. However, the optimal sequence of treatment and the optimal combinations both for frontline and relapsed and/or refractory myeloma is currently unknown. An important challenge will be the identification of these patient subsets that will benefit most from certain combinations of novel agents. Therefore, future studies should incorporate analysis of biomarker components that can predict the safety and effectiveness of new drugs, to select the appropriate patients to be treated with these new drugs.

This review provides an overview of the current evolving treatment strategies and challenges in the care of patients with relapsed and/or refractory multiple myeloma (RRMM).

Clonal Evolution and Competition in Multiple Myeloma {#Sec2}
====================================================

Keats et al. \[[@CR4]\] found that approximately one-third of patients with MM have stable genomes, particularly those with low-risk hyper-diploid disease, potentially explaining their more favorable clinical outcomes. In another one-third of patients, genome changes over time were evident that are best explained by the existence of clonal heterogeneity at diagnosis. In the final one-third of patients, a pattern consistent with linear evolution was the dominant characteristic. The last two groups included the high-risk patients, suggesting that high-risk tumors are less stable and more prone to change with time \[[@CR4]\]. Also, mutations involving individual genes are adding a further level of complexity to the concept of clonal evolution and heterogeneity. Additional studies have shown the importance of the evolution of adverse prognostic markers at relapse including the enrichment of MAPK gene mutations, adverse chromosomal prognostic markers, and biallelic inactivation of tumor suppressor genes \[[@CR5]--[@CR8]\].

These findings might have therapeutic implications. For instance, especially in the high-risk and relapsed and refractory setting, combination therapies, which confer anti-myeloma effects through different and complementary mechanisms, presumably targeting all coexisting disease sub-clones, will probably be particularly important, while sequential single-agent therapy might lead to preferentially eradicating the more indolent clone, allowing the more aggressive ones to expand. Another consideration might be that currently, retreatment of a patient with a regimen on which they have previously progressed is avoided because of the assumption of continued drug resistance. However, with intervening therapy, a sensitive sub-clone may have re-emerged, and retreatment might be effective again. Furthermore, certain mutations in some individual genes may have implications for targeted therapy. Nevertheless, the waves of different multiple myeloma clones evolving during the natural course of disease and the shifts in dominant and subdominant clones emerging during therapy and relapse are still chiefly an unraveled field and these findings require additional exploration before they may lead to personalized treatment care in MM \[[@CR9]\].

Prognostic Factors {#Sec3}
==================

The course of MM is highly variable and depends on a variety of prognostic factors, including unfavorable high-risk cytogenetic abnormalities \[del17p, t(4;14), ampl1q, t(14;16), t(14;20)\], a high-risk gene expression profile, high serum levels of lactodehydrogenase (LDH), a high International Staging System (ISS) stage (defined by the level of serum albumin and β2-microglobulin), presence of extramedullary disease, presence of circulating plasma cells, or rapid progression or relapse during or after treatment \[[@CR10], [@CR11]\]. Also, the proliferative rate of the malignant plasma cell is a prognostic determinant, which can be measured as the plasma cell labeling index \[[@CR12]\] or by using Ki-67 antigen expression \[[@CR13]\].

Basic staging (albumin, β2-microglobulin) does not necessarily represent the biologic heterogeneity at the time of diagnosis. This problem has recently been addressed by the revised ISS (R-ISS) \[[@CR14]\]. The R-ISS risk stratification includes serum albumin and β2-microglobulin for ISS staging, but also serum LDH and the cytogenetic abnormalities t(4;14), t(14;16) and/or del17p to define high-risk, normal-risk and low-risk disease in newly diagnosed multiple myeloma. However, for MM patients in the relapse setting, the value of the prognostic score is yet unknown. Gene expression profiling (GEP) may identify patients with an unfavorable outcome, as has been shown with the EMC92 score, based on the prognostic signature from the 65/GMMG-HD4 clinical trial, and UAMS70 score, and UAMS80 score based on the 70- and 80-gene prognostic signatures by the UAMS researchers \[[@CR15]--[@CR17]\].

When combining 20 risk markers, including t(4;14) and del17p (FISH), EMC92, UAMS70 and ISS, it was shown that the EMC92-ISS combination was the strongest predictor for overall survival. This combination identified four risk groups of which the median overall survival was only 24 months for the highest risk and was not reached for the lowest risk group. Also, extramedullary disease, which may be more easily detected nowadays by PET-CT scan \[[@CR18]\], and circulating plasma cells are independent prognostic markers \[[@CR19]\].

Definitions of Relapsed Multiple Myeloma {#Sec4}
========================================

RRMM patients present a heterogeneous group of patients. The IMWG published definitions of relapsed MM, as well as refractory myeloma, and also treatment indications in 2006, 2009 and 2011 \[[@CR20]--[@CR22]\]. RRMM is regarded as a recurrence of the disease in patients treated to the point of maximal response and who then experience progression based on objective laboratory and radiologic criteria as depicted in Table [1](#Tab1){ref-type="table"}.Table 1International Myeloma Working Group relapse criteria for multiple myelomaDefinition of relapsed multiple myelomaRecurrence of the disease after prior response, defined on:\
*Objective laboratory criteria:*\
≥ 25% increase of the serum M-protein (the absolute increase must be ≥ 5 g/L)\
or urine monoclonal protein (the absolute increase must be ≥ 200 mg/24 h)\
or ≥ 25% difference between involved and uninvolved serum free light chains (the absolute increase must be ≥ 100 mg/L) from its nadir, respectively,\
*Or objective radiologic criteria:*\
the definite development of new lytic bone lesions or soft tissue plasmacytomas\
or definite increase in the size of existing bone lesions or soft tissue plasmacytomas increase, defined as a ≥ 50% increase and at least increase of ≥ 1 cm as measured serially by the sum of the products of the cross-diameters of the measurable lesion\
Or the development of hypercalcemia that can be attributed solely to the plasma cell proliferative disorder.\
In patients with non-secretory disease, relapse is defined as an increase of the bone marrow plasma cell percentage (the absolute rise in % must be ≥ 10%).

Refractory to prior treatment indicates progressive disease on last prior treatment, best response of stable disease to last prior treatment, or progressive disease within 60 days of stopping prior therapy. There are two categories of refractory myeloma: "relapsed-and-refractory myeloma" and "primary refractory myeloma". Relapsed and refractory myeloma is defined as relapse in patients who must have achieved at least minimal response (MR), which either becomes non-responsive while on salvage therapy or progresses within 60 days of last treatment \[[@CR20], [@CR23]\]. Primary refractory myeloma is defined as disease that is non-responsive; patients who have never achieved a MR or better with any therapy \[[@CR23]\]. Double-refractory MM refers to disease refractory to both proteasome inhibitors and immunomodulatory drugs.

Treatment Indication for Relapsed and/or Refractory Multiple Myeloma {#Sec5}
====================================================================

In general, an indication for relapse treatment can be defined on clinical relapse and/or on significant M-protein (biochemical) relapse. Clinical relapse is defined as either the appearance or reappearance of one or more CRAB-criteria (MM-associated symptoms, including hyper**c**alcemia, **r**enal failure, **a**nemia, **b**one disease criteria), as well as increase in size of plasmacytomas (\> 50%). Biochemical relapse is defined as doubling of the M-protein in two consecutive measurements separated by ≤ 2 months; or an increase in the absolute levels of serum M-protein by ≥ 10 g/L, or urine M-protein increase by ≥ 500 mg/24 h, or increase of the involved free light chain (FLC) level by ≥ 200 mg/L (plus an abnormal FLC ratio) in two consecutive measurements separated by ≤ 2 months \[[@CR22]\].

Treatment should be considered as well at the stage of biochemical relapse in the presence of high risk factors. These include aggressive disease at diagnosis, a short treatment-free interval with a suboptimal response to the previous treatment line, imminent risk for organ dysfunction such as previous light chain-induced renal impairment, or unfavorable cytogenetics as t(4;14) or del17p \[[@CR24]\].

Treatment Selection {#Sec6}
===================

Since MM predominantly affects elderly patients (median age at diagnosis is 69 years, and almost one-third of patients is older than 75 years of age), the evaluation of patients' fitness is an important element when choosing therapy for the elderly MM patients. However, patients older than 65 years of age are highly heterogeneous with different levels of vulnerability. Based on this concept, the IMWG developed a frailty score including age, functional status, and comorbidities, in order to determine the frailty status of patients and the feasibility of treatment. According to this score, elderly patients are defined as fit, intermediate fit, and frail. This frailty score predicts mortality and the risk of toxicity in elderly myeloma patients \[[@CR25]\]. The assessment of frailty may be helpful to choose the most appropriate therapeutic approach and to define treatment goals for each patient subgroup. Fit patients can be eligible for full-dose triplet-therapies, whereas unfit and frail patients may benefit from less-intensive triplet-regimens, doublet regimens or dose reductions according to expert-based local guidelines. Consistently, the goal of therapy is different in these groups: the goal of therapy for fit patients might be to achieve a complete remission and improve survival, while in frail patients it might be more important to improve and preserve the quality of life for as long as possible \[[@CR25]--[@CR27]\].

Other factors are important when selecting second-line therapy; for example, to consider high-risk features at the time of relapse and duration and depth of response to previous treatment. Furthermore, previous tolerability is an important consideration; factors like myelosuppression, neuropathy and thrombosis may influence the choice and dosing of therapy. In this respect, additional challenges arise towards the end stage of MM when many patients experience cytopenia due either to extensive bone marrow involvement or exhausted hematopoiesis due to prior therapies. Furthermore, treatment choices are also influenced by preferences and expectations of the patients and their families \[[@CR28]\]. Figure [1](#Fig1){ref-type="fig"} shows factors influencing the choice of therapy at relapse.Fig. 1Factors influencing choice of therapy at relapse. *LDH* lactodehydrogenase, *DVT* deep venous thrombosis, *PNP* polyneuropathy, *HDT*-*ASCT* high-dose therapy-autologous stem cell transplantation, *IMiDs* immunomodulatory drugs, *PIs* proteasome inhibitors

New Treatment Options {#Sec7}
=====================

A better understanding of the biology of the disease has led to the development of new, effective agents that are able to overcome resistance to conventional therapies, and therefore prolong survival of MM patients. In this respect, several new anti-myeloma agents have shown activity, including next-generation IMiDs (pomalidomide) and proteasome inhibitors (carfilzomib, ixazomib), but also compounds with different mechanisms of action such as histone deacetylase inhibitors (HDACi), kinesin spindle protein inhibitors, and mTOR inhibitors \[[@CR29]\].

Furthermore, the immune system is considered significantly compromised in MM patients. Multiple mechanisms of immune evasion by MM cells have been described, including reduced expression of tumor antigens and human leukocyte antigen (HLA) molecules by the malignant plasma cells \[[@CR30]--[@CR32]\], enhanced expression of inhibitory ligands, such as programmed cell death ligand 1 (PD-L1) by the plasma cells \[[@CR33]--[@CR36]\], and recruitment of regulatory T cells (Tregs) \[[@CR37], [@CR38]\] and myeloid-derived suppressor cells (MDSCs) \[[@CR39]--[@CR42]\], both of which can contribute to immune suppression. Therefore, also immunotherapy, aimed at engaging the immune system in the fight against malignant cells, is an attractive concept in MM treatment. A number of different strategies can be distinguished, such as monoclonal antibody (mAb) therapy, chimeric antigen receptor (CAR) T cells, checkpoint inhibition, and vaccination. Table [2](#Tab2){ref-type="table"} shows novel agents including next-generation novel drugs and immunotherapeutic developments in MM.Table 2Newer generations and classes of anti-myeloma drugsClassMechanism of action*Immunomodulatory agents*\
Thalidomide\
Lenalidomide\
PomalidomideDirect antitumor activity, anti-angiogenic effects and indirect immunomodulatory effects*Proteasome inhibitors*\
Bortezomib\
Carfilzomib\
Ixazomib\
Marizomib\
OprozomibProteasome inhibition leads to accumulation of proteins within the myeloma cell resulting in growth arrest and cell death*Histone deacetylase inhibitors*\
Panobinostat\
Vorinostat\
RomidepsinIncreased acetylation of histone (and some non-histone) proteins, which regulates gene expression of tumor suppressors, transcription factors and oncogenic proteins. Interference with protein degradation via the aggresome pathway, an alternative protein degradation process pathway to the proteasome pathway. Interference with the interaction of myeloma cells and the microenvironment*Monoclonal antibodies (mAbs)*\
Elotuzumab (anti-CS1/anti-SLAM7)\
Daratumumab (anti-CD38)\
SAR650984 = isatuximab (anti-CD38)\
MOR202 (anti-CD38)\
Denosumab (anti-RANKL)\
Siltuximab (anti-IL6)\
IPH2101 (anti-KIR2DL1/2/3)Direct induction of apoptosis via activation or inhibition of target molecules. CDC, ADCC, ADCP. Immuno-modulation via altered immune subset activation.\
Other new developed mAbs are directed against cellular or non-cellular components of the microenvironment resulting in inhibition of angiogenesis, neutralization of growth factors, enhancing host antitumor immune responses, and modulation of mediators of bone disease*Checkpoint inhibitors*\
i.e. Nivolumab\
PembrolizumabCheckpoint inhibitors target PD1 or PD-L1/PD-L2 whereby restoring T cell activity against tumor cells*mTOR inhibitors*\
Everolimus\
TemsirolimusDownstream mediator of the PI3 K/Akt pathway regulating translation of proteins involved in myeloma growth and survival*Akt inhibitors*\
PerifosinePrevention of cell cycle protein translation and inducement of G1 arrest*MEK inhibitors*\
SelumetinibDecreased proliferation and survival of MM cells as well as inhibition of osteoclast bone resorption*Kinesin spindle protein inhibitors*\
Array-520To arrest cells in mitosis and to induce apoptosis due to degradation of the BCL2 family survival protein MCL-1*BH3 mimetics*\
ABT-199 (venetoclax)\
ABT-263 (navitoclax)\
Obatoclax mesylateBinds to anti-apoptotic BCL2 family members, whereby inhibiting the binding of pro-apoptotic proteins*Vaccines*\
PVX-410Cocktail of HLA-A2--specific peptides which can trigger HLA-restricted expansion and activation of MM-specific T cells*CAR T*\
i.e. against CD19, CD38, CS1, BCMATargeted T cell therapy directed against a cell-surface antigen on malignant cells*Selective inhibitor of nuclear transport (SINE)*\
SelinexorRetention and activation of tumor-suppressor proteins (as NF-kB, p53 and FOXO), induction of the glucocorticoid receptor in the presence of steroids and also suppressing the oncoprotein expression as Myc and cyclin D*CDC* complement-dependent cytotoxicity, *ADCC* antibody-dependent cellular cytotoxicity, *ADCP* antibody-dependent cellular phagocytosis, *SLAM7* signaling lymphocyte-activating molecule-related receptor family 7, *RANKL* receptor activator of nuclear factor kappa-B ligand, *IL6* interleukin 6, *PD1* programmed death 1, *PD*-*L1* programmed death-ligand 1, *PD*-*L2* programmed death-ligand 2, *mTOR* mammalian target of rapamycin, *MM* multiple myeloma, *CAR* chimeric antigen receptor, *BCMA B* cell maturation antigen

In the following section there will be a brief discussion of the most promising next-generation novel agents, novel drugs with different mechanisms of action, and immune-based approaches for the treatment of MM. Finally, treatment recommendations are given for first and subsequent relapsed myeloma.

Next-Generation Novel Agents {#Sec8}
----------------------------

### IMiDs {#Sec9}

Pomalidomide is a next-generation oral immunomodulatory agent with strong direct anti-myeloma activity. It has potent immune-modulatory effects, as the activation of natural killer cells and inhibition of Tregs, and interferes with stroma cell-support in the bone marrow \[[@CR43]\]. The randomized phase III trial MM-003 compared pomalidomide and low-dose dexamethasone with high-dose dexamethasone in RRMM patients who have received prior bortezomib- and lenalidomide-based therapies. The median prior lines of treatment were 5 in both treatment arms. After a median follow-up of 10 months the overall response rate (ORR), defined as partial response or better, was 31% for patients treated with pomalidomide and low-dose dexamethasone vs 10% for patients treated with high-dose dexamethasone alone. In patients with at least partial response, median duration of response was 7.0 and 6.1 months, respectively. The pomalidomide and low-dose dexamethasone arm showed a significantly longer progression-free survival (PFS) of 4.0 vs 1.9 months, and overall survival (OS) of 12.7 vs 8.1 months \[[@CR44]\]. The efficacy and favorable toxicity profile of this regimen has been confirmed in the STRATUS trial, a large phase III study evaluating pomalidomide plus low-dose dexamethasone in patients relapsed/refractory to bortezomib- and lenalidomide-based therapies. This study reported a median PFS of 4.6 months and a median OS of 12.9 months \[[@CR45]\]. Pomalidomide has been approved by the US Food and Drug administration (FDA) and European Medicines Agency (EMA) in 2013 for its use alone or in combination with dexamethasone in RRMM patients who have received at least two prior lines of treatment including lenalidomide and bortezomib.

Interestingly, data from the Intergroupe Francophone du Myélome (IFM) study indicate that pomalidomide combined with dexamethasone is also active in adverse cytogenetic patients with early RRMM, particularly in patients with del(17p) \[[@CR46]\].

Several clinical trials evaluated the role of pomalidomide-based combination regimens in RRMM patients. The addition of cyclophosphamide to pomalidomide and dexamethasone has been found to increase both response rates and PFS; pomalidomide-cyclophosphamide-prednisone (PCP) in relapsed and/or refractory pomalidomide-naive MM patients, treated with a median of 3 prior lines of treatment, showed an ORR of 51% and a median PFS of 10.4 months \[[@CR47]\]. Furthermore, a recent randomized phase II trial compared the combination pomalidomide-cyclophosphamide-dexamethasone with pomalidomide-dexamethasone in heavily pretreated pomalidomide-naive RRMM patients with a median of 4 prior treatment lines, and demonstrated an ORR of 64.7 vs 38.9% and a PFS of 9.5 vs 4.4 months, respectively \[[@CR48]\].

The combination of the IMiD lenalidomide with cyclophosphamide and prednisone (REP-therapy; Revlimid, Endoxan, Prednisone) has recently been evaluated in a prospective phase I/II clinical trial. Importantly, all patients in this trial had lenalidomide-refractory MM. The maximal tolerated dose (MTD) was defined as 25 mg lenalidomide (days 1--21/28 days cycle), combined with continuous cyclophosphamide (50 mg/day) and prednisone (20 mg/day). At the MTD, the ORR was 67% with a median PFS and OS of 12.1 and 29.0 months, respectively \[[@CR49]\]. In this study, lenalidomide plus cyclophosphamide and prednisone had a generally favorable tolerability profile, with the most frequent grade 3--5 adverse events being myelosuppression \[neutropenia (22%) and thrombocytopenia (22%)\], and infections (21%), consistent with the observed toxicities in MM patients treated with lenalidomide-dexamethasone \[[@CR49]--[@CR51]\].

Furthermore, encouraging results were shown from the phase I/II trial combining carfilzomib, pomalidomide and dexamethasone in RRMM with an ORR of 58%. With a median follow-up period of 10 months, the median PFS was 9.5 months and the median OS was not yet reached. The ORR for the high-risk patients was 44% \[[@CR52]\].

Altogether, combination strategies with IMiDs in the RRMM treatment setting have been shown to be effective and tolerable. The most frequent pomalidomide-related adverse events are myelosuppression, fatigue, and infections. Peripheral neuropathy, rash, gastrointestinal complaints, and muscle cramps are rare described adverse events. Provided that thrombosis prophylaxis is given, thromboembolic events are also rare.

### Proteasome Inhibitors {#Sec10}

Carfilzomib is a second-generation proteasome inhibitor that irreversibly and selectively inhibits the chymotrypsin-like site of the proteasome. Carfilzomib has been approved by the FDA in 2012 and the EMA in 2015 as a single agent for the treatment of patients with relapsed and refractory myeloma previously treated with lenalidomide and bortezomib.

As monotherapy in RRMM patients, carfilzomib induced an ORR of 23.7% with a median duration of response of 7.8 months and a median OS of 15.6 months \[[@CR53]\]. In the phase III FOCUS trial, 315 patients with RRMM were randomized between single-agent carfilzomib vs low-dose steroids with or without continuous low-dose oral cyclophosphamide. The control arm received 30 mg oral prednisone or 6 mg oral dexamethasone. The addition of 50 mg oral cyclophosphamide to the control group was optional; however, 94.8% of patients received this additional therapy. The OS in the carfilzomib group was 10.2 months, compared to 10.0 months (*p* = 0.42) in the control group. There was a slight difference in favor of carfilzomib in ORR (19.1% vs 11.1%, *p* = 0.03); however, this was not translated into an increase of PFS \[3.7 and 3.3 months for the carfilzomib and control group, respectively (*p* = 0.25)\]. The failure of the study to show differences with the control arm was probably due to the high efficacy of additional cyclophosphamide in the control group. The addition of cyclophosphamide to novel agents, for instance thalidomide, bortezomib, and lenalidomide, has shown significantly increased response rates \[[@CR54]--[@CR56]\] even in the setting of the addition of cyclophosphamide to lenalidomide in lenalidomide-refractory MM \[[@CR49]\].

In the ASPIRE trial, relapsed MM patients were randomized between carfilzomib-lenalidomide-dexamethasone and lenalidomide-dexamethasone, which resulted in an ORR of 87 vs 67% and in a PFS of 26.3 vs 17.6 months respectively \[[@CR57]\] (Table [3](#Tab3){ref-type="table"}).Table 3Selected clinical phase III combination studies with lenalidomide in the RRMM setting (1-3 prior lines, in lenalidomide-naive or lenalidomide-sensitive MM patients)Study*N*Median lines of prior treatmentORR (%)TreatmentMedian PFS (m)PFS HR (95% CI)Median OS (m)OS HR (95% CI)Pollux \[[@CR82]\]5691 (1--11)93 vs 76DRd vs RdNE vs 18.40.37 (0.27--0.52)NE vs NE0.64 (0.40--1.01)Aspire \[[@CR57]\]7922 (1--3)87 vs 67KRd vs Rd26.3 vs 17.60.69 (0.57--0.83)\
*p* = 0.00012--yr: 73 vs 65%0.79 (0.63--0.99)\
*p* = 0.04Eloquent2 \[[@CR72], [@CR124]\]6462 (1--4)79 vs 66ERd vs Rd19.4 vs 14.90.70 (0.57--0.85)\
*p* \< 0.00143.7 vs 39.60.77 (0.61--0.97)\
*p* = 0.257Tourmaline- MM1 \[[@CR61]\]7222 (1--3)78 vs 72IRd vs Rd20.6 vs 14.70.74 (0.59--0.94)\
*p* = 0.012NE vs NENE*RRMM* relapsed and/or refractory multiple myeloma, *N* number, *ORR* overall response rate, *PFS* progression-free survival, *m* months, *HR* hazard ratio, *CI* confidence interval, *OS* overall survival, *DRd* daratumumab-lenalidomide-daratumumab, *RD* lenalidomide-dexamethasone, *KRd* carfilzomib-lenalidomide-dexamethasone, *ERd* elotuzumab-lenalidomide-dexamethasone, *IRd* ixazomib-lenalidomide-dexamethasone, *vs* versus, *NE* non-evaluable

The ENDEAVOR study compared carfilzomib-dexamethasone with bortezomib-dexamethasone in RRMM patients. The ORR of carfilzomib-dexamethasone was superior with 77% compared to 63% for bortezomib-dexamethasone in this study. Carfilzomib-dexamethasone also showed a longer PFS (18.7 vs 9.4 months) \[[@CR58]\] (Table [4](#Tab4){ref-type="table"}). Data from these trials have led to the approval of these triplet and doublet combination treatments with carfilzomib for MM patients who have received at least one previous line of therapy.Table 4Selected clinical phase III combination studies with PIs bortezomib in the RRMM setting (1--3 prior lines, in bortezomib-naive or bortezomib-sensitive MM patients)Study*N*Median lines of prior treat-mentORR (%)TreatmentMedian PFS (m)PFS HR (95% CI)Median OS (m)OS HR (95% CI)Castor \[[@CR86]\]4982 (1--10)83 vs 63DVd vs VdNE vs 7.20.39 (0.28--0.53)\
*p* \< 0.0001NE vs NE0.77 (0.47--1.26)Endeavor \[[@CR58]\]9292 (1--2)77 vs 63Kd vs Vd18.7 vs 9.40.53 (0.44--0.65)\
*p* \< 0.0001NE vs 24.30.79 (0.58--1.08)\
*p*  = 0.13Panorama-1 \[[@CR67], [@CR135]\]7681 (1--3)61 vs 57PVd vs Vd12.0 vs 8.10.63 (0.52--0.76)\
*p* \< 0.000140.3 vs 35.80.94 (0.69--1.10)\
*p* = 0.54*RRMM* relapsed and/or refractory multiple myeloma, *N* number, *ORR* overall response rate, *PFS* progression-free survival, *m* months, *HR* hazard ratio, *CI* confidence interval, *OS* overall survival, *DVd* daratumumab-bortezomib-daratumumab, *Vd* bortezomib-dexamethasone, *Kd* carfilzomib-dexamethasone, *PVd* panobinostat-bortezomib-dexamethasone, *vs* versus, *NE* non-evaluable

Carfilzomib has a favorable side-effect profile compared to bortezomib, especially the low incidence of treatment-emerging peripheral neuropathy, and after prolonged treatment, makes it an attractive agent to incorporate in treatment protocols. On the other hand, a combined safety analysis of four phase II trials of single-agent carfilzomib reported an overall cardiac-related adverse events rate of any grade of 22%, especially dyspnea, hypertension, and heart failure \[[@CR59]\]. These cardiac adverse events were predominantly grade 1 and 2 adverse events and mostly transient, and resolved in most patients without dose adjustments \[[@CR59]\]. Carfilzomib-associated cardiotoxicity ≥ grade 3 cardiac failure occurred in 4.8% of patients; most of these patients had a history of cardiovascular events (74%) or had baseline cardiac risk factors (70%) \[[@CR59]\]. Tight blood pressure control and baseline cardiac assessment has been described to lower the cardiac adverse event rate. Further studies to better understand the biological basis of carfilzomib-related cardiotoxicity to develop guidelines for appropriate prevention and management are ongoing \[[@CR60]\].

Ixazomib, the first oral proteasome inhibitor, was tested in the TOURMALINE MM phase III study, for patients with relapsed, refractory, or both relapsed and refractory MM, who had received one to three prior therapies and were not refractory to prior lenalidomide therapy or proteasome inhibitor--based therapy. This study demonstrated that the combination of ixazomib-lenalidomide-dexamethasone was superior to lenalidomide and dexamethasone with an ORR of 78% compared to 72%, and a median PFS of 20.6 months compared to 14.7 months in the control group \[[@CR61]\] (Table [3](#Tab3){ref-type="table"}). Ixazomib is associated with a favorable toxicity profile with a lower risk of polyneuropathy in comparison to bortezomib. However, a higher rate of gastrointestinal adverse events has been reported. Ixazomib-lenalidomide-dexamethasone is currently tested in a large phase III study in newly diagnosed MM patients, whereas two other phase-III studies are testing ixazomib as maintenance therapy after autologous stem-cell transplantation (ASCT) in younger MM patients and after standard induction therapy in elderly patients.

Marizomib and oprozomib are new-generation proteasome inhibitors currently tested in phase I-II clinical trials. Marizomib inhibits all three proteolytic sites of the enzyme, showing a greater activity on myeloma cells compared to bortezomib in preclinical models. Oprozomib is structurally related to carfilzomib, with the advantage of oral administration. Of note, encouraging activity of marizomib has been reported in patients with involvement of MM in their central nervous system, which has normally limited therapeutic options \[[@CR62]\].

Novel Drugs with Different Mechanisms of Action {#Sec11}
-----------------------------------------------

### Histone Deacetylase Inhibitors {#Sec12}

Controlling the coiling and uncoiling of DNA around histones is essential for gene expression. Histone acetyl transferases acetylate, the lysine residues in core histones, resulting in less compact and transcriptionally more active chromatin. Conversely, histone deacetylases (HDACs) remove the acetyl groups from the lysine residues leading to the formation of a condensed and transcriptionally silenced chromatin. Inhibition of this process results in increased gene expression and in cell cycle arrest, differentiation and/or apoptosis. Histone deacetylase inhibitors (HDACi) are a novel class of agents that target these HDAC enzymes, which are involved in the unfolded protein response pathways and in the epigenetic regulation of gene expression, promoting cell proliferation and cell death. Overexpression of HDACs has been reported in several cancers, including MM \[[@CR63]\]. HDACi exert their antitumor activity via the inhibition of these HDACs that leads to increased acetylation of histone (and some non-histone) proteins, which regulates the expression of tumor suppressors, transcription factors and oncogenic proteins. Increased histone acetylation by panobinostat also blocks the aggresome pathway, an alternative protein degradation process that may enable MM cells to develop resistance to proteasome inhibitors \[[@CR64]\].

Despite demonstration of promising preclinical activity, monotherapy with the pan-HDACi vorinostat failed to provide any clinical benefit, while its use in combination with bortezomib resulted in a relevant increase in toxicity \[[@CR65], [@CR66]\]. More promising clinical results have been reported with the pan-HDACi panobinostat that has been granted fast-track approval by the FDA in combination with bortezomib and dexamethasone for the treatment of RRMM patients who have received at least two prior regimens, including bortezomib and an IMiD. This fast-track approval is based on increased PFS for the triple combination of panobinostat with bortezomib and dexamethasone compared to bortezomib and dexamethasone alone, demonstrated in a phase III clinical study \[[@CR67]\] (Table [4](#Tab4){ref-type="table"}). In this study, panobinostat plus bortezomib and dexamethasone had a generally manageable tolerability profile, with the most frequent grade 3--4 adverse events being myelosuppression, diarrhea, asthenia or fatigue, peripheral neuropathy and pneumonia \[[@CR67]\]. The simultaneous blockade of the aggresome and ubiquitin--proteasome pathway by panobinostat and bortezomib may explain their synergistic antitumor activity when used in combination.

### Monoclonal Antibody Therapy {#Sec13}

Monoclonal antibodies (mAbs) are already a widely used treatment modality in hematology, with rituximab being the most prominent example. This agent was approved for the treatment of lymphoma by the FDA in 1997 and by the EMA in 1998 \[[@CR68]\], and is now considered a standard therapy in lymphoma that has had a major impact on survival \[[@CR69]\]. Until recently, no appropriate mAbs were available for MM. However, a large series of monoclonal antibodies targeting different epitopes on myeloma cells or immune and stromal cells are emerging with various candidates having been FDA- and EMA-approved now, with others in late-stage clinical development \[[@CR70]\]. The targets for monoclonal antibody development in MM have been either surface proteins or cytokines considered to be relevant for disease biology. Until now, two monoclonal antibodies, elotuzumab and daratumumab, have been approved for the treatment of patients with relapsed MM.

#### Elotuzumab {#Sec14}

Elotuzumab is a humanized monoclonal antibody targeting CS1, a cell surface glycoprotein and member of the signaling lymphocyte-activating molecule-related receptor family 7 (SLAM7), highly expressed on virtually all MM cells, with lower expression on natural killer cells and little or no expression in normal tissue \[[@CR71]\]. The role of CS1 in the pathogenesis of MM is still unclear. Elotuzumab works mainly via antibody-dependent cellular cytotoxicity (ADCC). Elotuzumab as a single agent has shown no or little activity with stable disease in approximately 25% of patients and no objective responses. However, combination therapy of elotuzumab with lenalidomide and dexamethasone has revealed a favorable safety profile and encouraging response rates with at least PR in 79% vs 66% of patients treated with lenalidomide and dexamethasone in relapsed MM patients (Eloquent-2 study) \[[@CR72]\]. The median PFS was 19.4 months for the patients treated with elotuzumab-lenalidomide-dexamethasone vs 14.9 months for the patients treated with lenalidomide-dexamethasone \[HR 0.70 (0.57--0.85)\], while the OS was 43.7 vs 39.6 months, respectively \[HR 0.77 (0.61--0.97)\] \[[@CR72]\] (Table [3](#Tab3){ref-type="table"}).

#### Daratumumab {#Sec15}

Another mAb that recently became available for the treatment of MM patients is daratumumab, a fully human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody, that specifically binds to a unique epitope present on the CD38 molecule. CD38 is a multifunctional cell surface protein that possesses receptor as well as enzyme functions. As a transmembrane receptor and through its binding to CD31, CD38 is involved in leukocyte adhesion, activation and proliferation \[[@CR73]\]. In addition to this receptor function, CD38 acts as an ectoenzyme; CD38 is a cyclic ADP ribose hydrolase that regulates intracellular Ca^2+^ influx, leading to the activation of several signaling pathways, eventually leading to the efflux of adenosine, which has an immunosuppressive effect on cytotoxic T cells \[[@CR73]\]. Virtually all MM cells express high levels of CD38 on their cell surface \[[@CR74]\]. However, CD38 is also expressed, although to lower levels, on lymphoid and myeloid cells as well as on several non-hematopoietic tissues (i.e. pancreas, brain, and muscle) \[[@CR75]\]. Daratumumab binds CD38 with high affinity and induces myeloma cell death via complement-dependent cytotoxicity (CDC), ADCC, antibody-dependent cellular phagocytosis (ADCP), via CD38 signaling pathway modulation and via the induction of tumor cell apoptosis via FCγR crosslinking \[[@CR76]--[@CR78]\]. Daratumumab also induces indirect antitumor activity through the elimination of CD38-positive immunosuppressive cells (Tregs, Bregs, and MDSCs), leading to enhanced CD8+ T cell effector functions \[[@CR79]\]. Interestingly, similar activity on immunosuppressive cells has also been described with isatuximab, another CD38-targeted monoclonal antibody \[[@CR80]\].

Daratumumab has been evaluated as a single agent in two clinical studies in heavily pretreated RRMM patients. A pooled analysis of these studies has shown that daratumumab monotherapy is well tolerated and that in the 16 mg/kg cohort at least a partial response can be achieved in 31% of the patients with a median PFS and OS of 4.0 and 20.1 months, respectively \[[@CR81]\]. As a result, the FDA and EMA approved daratumumab monotherapy for MM patients who have received three or more prior lines of therapy, including a PI and an IMiD, or who are double refractory to a PI and an IMiD.

Also for daratumumab, combination therapies engage stronger effects; combination therapy of daratumumab with lenalidomide and dexamethasone has revealed at least PR in 93% (including 43% CR/sCR) vs 76% (including 19% CR/sCR) of patients treated with lenalidomide and dexamethasone in a phase III randomized clinical trial in relapsed MM patients (Pollux study) \[[@CR82], [@CR83]\]. Importantly, minimal residual disease (MRD) negativity was more common in daratumumab-lenalidomide-dexamethasone (DRd) patients than in lenalidomide-dexamethasone (Rd) patients (22.4 vs 4.6% MRD negativity, respectively, defined with next-generation sequencing with a sensitivity threshold of 10^−5^) \[[@CR84]\]. Median PFS was not reached for the patients treated with DRd vs 18.4 months for the patients treated with Rd, respectively \[HR 0.37 (0.27--0.52)\]. Moreover, patients with high-risk cytogenetics (*n* = 33 in each treatment group) had longer PFS with DRd (median, not reached vs 8.3 months; HR, 0.30; *p* = 0.0019). Median OS was not reached in either group with a hazard ratio (HR) of 0.64 (0.40--1.01) \[[@CR82], [@CR83]\] (Table [3](#Tab3){ref-type="table"}). The phase III randomized Castor trial showed advantage of the addition of daratumumab to bortezomib/dexamethasone with at least PR in 83% (including 19% CR/sCR) for the patients treated with the triple combination vs 63% (including 9% CR/sCR) of patients treated with bortezomib and dexamethasone in relapsed MM patients \[[@CR85], [@CR86]\]. Here, MRD negativity was more common in daratumumab-bortezomib-dexamethasone (DVd) patients than in bortezomib-dexamethasone patients (7.2 vs 1.6% MRD negativity, respectively) \[[@CR84]\]. The median PFS was not reached for the patients treated with daratumumab-bortezomib-dexamethasone vs 7.2 months for the patients treated with bortezomib-dexamethasone \[HR 0.39 (0.28--0.53)\], while the median OS was not reached in both groups with a HR of 0.77 (0.47--1.26) \[[@CR85], [@CR86]\] (Table [4](#Tab4){ref-type="table"}). Due to the valuable safety profile and encouraging efficacy data in these trials in the RRMM treatment setting, daratumumab is currently tested in extensive phase III randomized trials in which daratumumab is added to upfront treatment schemes for transplant-eligible as well as for transplant-ineligible patients. When proven effective, mAbs may become a standard part of upfront therapy. In line with the development of other monoclonal antibodies (i.e. rituximab), a subcutaneous administration of daratumumab is currently evaluated with the objectives to limit the time of infusion and the rate of infusion-related reactions, the most important side effect of daratumumab.

Other monoclonal antibodies targeting CD38 are currently being evaluated in MM. Isatuximab is an IgG chimeric antibody that has already demonstrated clinical activity alone and in combination strategies in relapsed MM patients \[[@CR87], [@CR88]\]. MOR202 is another CD38 IgG human antibody that has shown promising activity alone and in combination with pomalidomide and lenalidomide in relapsed MM patients \[[@CR89]\].

### Checkpoint Inhibitors {#Sec16}

Programmed cell death-1 (PD-1, CD279) is a member of the CD28 receptor family. Its ligands, either PD-L1 (CD274) or PD-L2 (CD273), play a fundamental role in tumor immune escape by inhibiting immune effector functions. PD-1 expression is induced on antigen activated T cells and exhausted T cells and B cells; PD-L1 is mainly expressed by antigen-presenting cells (APC) and various non-hematopoietic cells; and PD-L2 is found on hematopoietic cells, including dendritic cells and macrophages. In cancer initiation and development, tumor cells suppress immune surveillance by using PD-L1 ligand to engage the PD1 receptor on T cells and inhibit T cell activation \[[@CR90]\]. Checkpoint inhibitors targeting PD1 or PD-L1 or PD-L2 therefore restore T cell activity against tumor cells and have emerged as a vital new therapeutic strategy. Notably, increased PD-L1 expression has been shown in multiple myeloma cells compared with healthy donor plasma cells \[[@CR33], [@CR36], [@CR91]--[@CR93]\] and increased PD-1 expression has been demonstrated on CD4+ T cells in multiple myeloma \[[@CR33], [@CR92]--[@CR94]\]. As a single agent, nivolumab, a PD-1 inhibitor, had minimal activity in relapsed MM, with a SD rate of 67% in a phase I trial; partial responses or better were not seen \[[@CR95]\]. Although immune checkpoint inhibition with PD-1 inhibitors had limited efficacy when the inhibitors are used as single agents, it has led to promising results when the inhibitors are combined with immunomodulatory drugs such as lenalidomide and pomalidomide \[[@CR96], [@CR97]\]. A recent trial with pembrolizumab and lenalidomide demonstrated an ORR of 74% in patients with two or more prior lines of treatment \[[@CR97]\]. A trial with pomalidomide and pembrolizumab showed an ORR of 60%, while these patients were heavily pre-treated, with a median of three prior lines of treatment and, importantly, 73% of these patients were refractory to both immunomodulatory drugs and proteasome inhibitors. PFS was 17.4 months, and OS not yet reached \[[@CR96]\]. However, recently the FDA placed partial and full clinical holds on trials with PD-(L)1 inhibitors in combination with immunomodulatory agents in patients with myeloma, chronic lymphatic leukemia, or lymphoma due to possible safety concerns. Further in-depth analyses are currently performed, meanwhile these trials are not enrolling any new patients.

### Vaccines {#Sec17}

Vaccination against cancer-specific antigens presents a promising strategy to modulate patient antitumor immune response, particularly in the setting of early-stage disease (i.e. in smoldering MM) or in the setting of minimal residual disease. The vaccine PVX-410 consists of a cocktail of HLA-A2--specific peptides derived from X-box binding protein 1, CD138, and SLAMF-7 MM antigens, which can trigger HLA-restricted expansion and activation of MM-specific T cells \[[@CR98]\]. Vaccination therapy combined with IMiDs and/or with anti--PD-1 mAbs might further enhance MM-specific immune responses.

### Chimeric Antigen Receptor T Cells {#Sec18}

Like monoclonal antibodies, chimeric antigen receptor (CAR) T cells are targeted therapies directed against a cell-surface antigen on malignant cells. However, CAR T cells are potentially more potent than mAbs and can establish long-lived immunity against the target antigen after a single infusion. CARs are engineered receptors that artificially confer specificity of T lymphocytes for native cell-surface antigens \[[@CR99]\].

For MM, CAR-T cells directed against e.g. CD38, CS1, B cell maturation antigen (BCMA), CD138, kappa light chain, NKG2D and CD44v6 have demonstrated preclinical anti-MM activity. Phase I clinical trials with CAR T cells, directed against BCMA, for example, are currently recruiting MM patients \[[@CR100]\] and have shown promising tumor cell reductions, even in high-risk and RRMM \[[@CR101], [@CR102]\].

Targeted Therapy in Multiple Myeloma {#Sec19}
====================================

Interaction of MM cells with bone marrow stromal cells (BMSCs) induces activation of MEK/ERK, JAK2/STAT3, and PI3 K/Akt signaling pathways, resulting in proliferation, survival, drug resistance, and migration of MM cells \[[@CR103]--[@CR105]\]. Various new anti-myeloma drugs interfere in these interactions and are currently being investigated in clinical trials, which includes RAF-inhibitors (sorafenib), BRAF inhibitors (vemurafenib), kinesin spindle protein inhibitors (ARRY-520), Akt inhibitors (perifosine), and BH3 mimetics (venetoclax) (Table [2](#Tab2){ref-type="table"}).

Sorafenib is a drug targeting the RAS-RAF-MEK-ERK pathway and inhibiting the actions of the vascular endothelial growth factor (VEGF). Since the RAS-RAF-MEK-ERK pathway is often mutated in MM, leading to uncontrolled growth of tumor cells, and VEGF is stimulating bone marrow neovascularization, sorafenib is a drug offering the potential for targeting two important pathogenic mechanisms involved in MM \[[@CR106]\]. However, sorafenib showed only minimal anti-myeloma activity as a single agent in RRMM patients with beneficial activity in 2 out of 11 heavily pretreated myeloma patients in one study \[[@CR107]\], and no objective responses observed in another study with 14 evaluable MM patients \[[@CR108]\].

Approximately 3--5% of MM patients have mutations in BRAF. Inhibitors like vemurafenib are highly active in BRAF-mutated patients, but the duration of response is usually limited due to the development of alternative activation pathways as increased expression of PDGFR or activations of NRAS mutations. Vemurafenib resulted in significant tumor reduction in patients with BRAF V600E mutations \[[@CR109]\].

Filanesib (ARRY-520) is a kinesin spindle protein inhibitor, which arrests cells in mitosis and induces apoptosis due to degradation of the BCL2 family survival protein MCL-1. A phase II study with filanesib with and without dexamethasone showed an ORR of 22% with a median duration of response between 5.1 and 8.6 months \[[@CR110]\].

The PI3 K/Akt/mTOR pathway is aberrantly active in MM and contributes to cell growth, proliferation, and survival. Akt is a nodal regulator of cellular survival pathways and might be an attractive target in cancer therapy. Many inhibitors of Akt are being developed. Perifosine is an oral Akt inhibitor inhibiting the nuclear translocation of NF-κB \[[@CR111]\]. The intrinsic apoptosis pathway in MM cells is regulated by a balance between anti-apoptotic (e.g. BCL-2, BCL-XL, MCL-1) and pro-apoptotic (e.g. BAX, BAK, NOXA) proteins \[[@CR112]--[@CR114]\]. Venetoclax is a new oral selective BCL-2 inhibitor that promotes apoptosis in MM cell lines and primary samples, particularly in myeloma cells with t(11;14), which express high levels of BCL-2 relative to BCL-XL and MCL-1 \[[@CR115]\]. Translocation (11;14) is seen in 15--20% of patients with MM \[[@CR116]\]. Recently, data of an open-label phase I study in RRMM patients, with a median of 5 prior therapies, showed an ORR of 21%. Confirming preclinical data, most responses \[12 out of 14 responses (86%)\] were reported in patients with t(11;14); the ORR was 40% (12 of 30 patients) in patients with t(11;14), while only 6% of the patients without t(11;14) responded to treatment with venetoclax \[[@CR116]\]. Responses in the t(11;14) group were durable, with a median duration of response of 9.7 months \[[@CR116]\]. Moreover, venetoclax in combination with bortezomib and dexamethasone achieved remarkable activity in a phase Ib study in RRMM patients with a median of 3 prior therapies. Specifically, the combination therapy was well tolerated, with an ORR of 67% (90% in patients not refractory to bortezomib; and 31% in patients who were refractory to bortezomib); with the MTD not reached. The clinical benefit was higher in patients with fewer lines of therapy, not refractory to bortezomib, and those with high BCL-2 expression \[[@CR117]\]. A phase III study for RRMM patients with 1--3 prior lines of therapy comparing venetoclax plus bortezomib and dexamethasone vs bortezomib and dexamethasone is ongoing. A common adverse side effect in MM is gastrointestinal toxicity. Serious adverse effects included pneumonia (8%) and sepsis (5%). Tumor lysis syndrome, a significant problem in chronic lymphocytic leukemia (CLL) patients, has not been observed.

Selinexor is a first-in-class selective inhibitor of nuclear export (SINE) and binds and inhibits protein exportin-1 (XPO-1), which is the nuclear exporter for the majority of tumor suppressor proteins. Selinexor induces retention and activation of the tumor-suppressor proteins NF-kB, p53 and FOXO; furthermore, selinexor induces the glucocorticoid receptor in the presence of steroids. Also, it suppresses oncoprotein expression as Myc and cyclin D. Promising preclinical data \[[@CR118]\] have led to phase I/II clinical trials. A phase IIb open-label, single-arm Selinexor Treatment of Refractory Myeloma (STORM) study evaluated selinexor in combination with low-dose dexamethasone in relapsed and refractory MM patients after a median of 7 prior therapies. Preliminary results show an ORR of 21% (with a similar response rate in patients with high-risk MM); a median duration of response of 5 months, a median PFS of 2.3 months, and a median OS of 9.3 months. Primary toxicities included thrombocytopenia, nausea, anorexia, fatigue, and anemia; aggressive supportive care was required \[[@CR119]\]. The combination of selinexor with bortezomib/dexamethasone, selinexor plus lenalidomide/dexamethasone and selinexor plus daratumumab/dexamethasone is under evaluation. Preliminary data on the selinexor-bortezomib combination show an ORR of 77% \[[@CR120]\].

Treatment Recommendations {#Sec20}
=========================

Treatment at First Relapse {#Sec21}
--------------------------

Three general approaches to the management of symptomatic disease relapse following initial ASCT may be considered: (i) reinduction therapy followed by salvage HDT-ASCT for transplant-eligible patients, (ii) reinduction therapy with double or triple regimens using combinations of novel therapies for relapsed MM until development of progressive disease, and (iii) participation in clinical trials to evaluate any of the prior and new therapeutic options. Currently, only limited comparative data are available to support one approach over another \[[@CR121]--[@CR123]\].

At the time of relapse when second-line treatment is necessary, it is currently advised that patients not previously treated with a novel agent, should be treated with a proteasome inhibitor-based regimen, or an IMiD-based regimen, or a combination of both. Patients previously treated with an IMiD-based regimen should preferably be treated with a proteasome inhibitor-containing regimen at relapse if there is IMiD-refractory disease. Patients initially treated with a proteasome inhibitor-containing regimen, should preferably be treated with an IMiD-containing regimen as second-line treatment.

In general, doublet or triplet regimens are preferred above single agents for inducing optimal effects. Recently, different phase III clinical trials with novel-agent based triplet combinations demonstrated superior response rates and prolonged disease control when compared with two-drug regimens in several randomized clinical trials, without adding any relevant additional toxicity \[[@CR57], [@CR58], [@CR61], [@CR67], [@CR72], [@CR82], [@CR86], [@CR124]\]. These triplet therapies are likely to play a key role in overcoming drug resistance and hold promise to further improve long-term outcomes of relapsed MM patients. Table [3](#Tab3){ref-type="table"} shows phase III clinical trials with triplet therapies with lenalidomide; Table [4](#Tab4){ref-type="table"} shows phase III clinical trials with combination therapies with bortezomib. Currently, there are many different options in the relapse setting and there are no phase III clinical trials that compare these options, head-to-head. Therefore, it is currently impossible to define the optimal sequence. Choice of therapy has to be adapted on an individual basis according to patient's characteristics, tumor features and prior treatment.

Although triplet therapies do not completely abrogate poor prognosis associated with high-risk cytogenetics, compared to doublet therapies, triplets improve PFS both in standard-risk and in high-risk patients \[[@CR57], [@CR61], [@CR72], [@CR125]\]. Therefore, high-risk patients should preferably be treated with triplet therapy at relapse. Age and comorbidities are also important factors to consider at the time of relapse. Triplets were superior to doublets, also in older patients and in patients with renal dysfunction; however, in these clinical trials frail patients and patients with end-stage renal disease were not included. Therefore, in frail elderly patients, the benefit of triplets is less evident, because they may be more toxic, particularly with regard to hematologic toxicity \[[@CR27], [@CR126], [@CR127]\]. More research in this specific patient group is needed.

Daratumumab combinations with lenalidomide-dexamethasone or bortezomib-dexamethasone have shown impressive beneficial HRs for PFS in favor of the triplets, with a HR for PFS of 0.37 and 0.39, respectively (Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}). Moreover, in these trials the number of patients with MRD negativity was 3.5--5 times higher in patients treated with triplets compared to the doublets. Even some patients with high-risk disease achieved MRD negativity \[[@CR84]\]. Therefore, CD38 antibody-based combinations are expected to be first choice in relapsed MM in the near future.

When transplant-eligible MM patients had sufficient benefit from upfront therapy with ASCT (\> 24 months remission period) or have not been treated with high-dose therapy and ASCT at frontline, then second-line induction therapy followed by high-dose therapy and ASCT is a valuable consolidation strategy \[[@CR122], [@CR128], [@CR129]\]. Allogeneic stem-cell transplantation and donor lymphocyte infusion for MM can induce graft-versus-myeloma immunity and long-term survivorship; however, the absence of a consistent OS benefit in comparative studies \[[@CR130]--[@CR132]\] and associated toxicities have prevented its widespread use. Allogeneic stem-cell transplantation may be considered for young patients with high-risk disease at the time of relapse, but preferably in the context of a clinical trial \[[@CR128], [@CR129]\].

Treatment recommendations for transplant-eligible and -ineligible patients are schematically depicted in Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}.Fig. 2Treatment recommendations for transplant eligible patients (or young, fit patients). *PI*, proteasome inhibitor; *IMiD*, immunomodulatory drugs; *DRd*, daratumumab-lenalidomide-daratumumab; *KRd*, carfilzomib-lenalidomide-dexamethasone; *IRd*, ixazomib-lenalidomide-dexamethasone; *ERd*, elotuzumab-lenalidomide-dexamethasone; *DVd*, daratumumab-bortezomib-daratumumab; *PanoVd*, panobinostat-bortezomib-dexamethasone; *VTd*, bortezomib-thalidomide-dexamethasone; *VCd*, bortezomib-cyclophosphamide-dexamethasone; *VRD*, bortezomib-lenalidomide-dexamethasone; *Rad*, lenalidomide-adriamycine-dexamethasone; *RD*, lenalidomide-dexamethasone; *Vd*, bortezomib-dexamethasone; *Kd*, carfilzomib-dexamethasone; *PR*, partial response; *HDT-ASCT*, high dose therapy-autologous stem cell transplantation; *allo-SCT*, allogeneic stem cell transplantation. 1 Allo-SCT may be considered in young, fit patients; only as part of clinical trial Fig. 3Treatment recommendations for transplant ineligible patients. *PI*, proteasome inhibitor; *IMiD*, immunomodulatory drugs; *dara*, daratumumab; *PR*, partial response; *RRMM*, relapsed and/or refractory multiple myeloma; *REP*, lenalidomide-cyclophosphamide-prednisone; *PCd*, pomalidomide-cyclophosphamide-dexamethasone; *PCP*, pomalidomide-cyclophosphamide-prednisone

Treatment Options for Double Refractory, Relapsed and Refractory Multiple Myeloma {#Sec22}
---------------------------------------------------------------------------------

Despite advances in MM therapy during recent years, virtually all myeloma patients eventually relapse. Second and later remissions tend to show shorter durations because of more aggressive tumor behavior at each relapse due to the selection of resistant clones and the development of refractory disease \[[@CR133]\]. The prognosis of MM patients who become refractory to the proteasome inhibitor bortezomib and/or carfilzomib and the IMiDs lenalidomide and/or pomalidomide is especially very poor with an event-free survival and OS of only 5 and 13 months, respectively \[[@CR8]\]. This clearly demonstrates that there is an ongoing need for additional active agents and novel treatment approaches with distinct mechanisms of action, especially for this category of MM patients. In the triplet vs doublet studies previously described (Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}), refractory patients have not been included and therefore benefit for this particular patient group is not known.

Myeloma patients relapsed or refractory to lenalidomide, bortezomib or both can nowadays be treated with novel generation immunomodulators, or novel generation proteasome inhibitors, or monoclonal antibody therapy. In the relapse setting, retreatment with an agent previously used is considered feasible, provided there was no acquired refractory status, and prior treatment with the regimen produced a clinically meaningful response of adequate duration with acceptable toxicity; in general, the minimal depth of response should be partial response, while the minimal duration of response should be at least 6 months \[[@CR134]\]. Another attractive option for the double refractory MM patient is the fully oral three-drug combination of lenalidomide, low-dose cyclophosphamide, and prednisone (REP), which showed an ORR of 67% in lenalidomide-refractory MM patients (66% of patients were double-refractory to lenalidomide and bortezomib). Median PFS and OS were 12.1 and 29.0 months, respectively \[[@CR49]\]. Importantly, REP therapy consists of a combination of drugs which are generally available in the (outpatient) clinic and is likely associated with lower costs of patient care.

Treatment recommendations for the RRMM setting are depicted in Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}.

Conclusions {#Sec23}
===========

Advances in the understanding of MM biology as well as the development of novel agents have substantially increased treatment options for RRMM patients over the last decade. Nowadays, choice of relapse treatment in MM is tailored, based on disease and patient characteristics, treatment history, and the needs and goals of the individual patient as summarized in Fig. [1](#Fig1){ref-type="fig"}.

Based on higher response rates and prolonged PFS, continuous treatment with three-drug regimens may be preferred for the young, fit and high-risk RRMM patients. In contrast, the goal of treatment for frail elderly relapsed MM patients is to preserve quality of life, which might be pursued by lower-dose intensity regimens with a beneficial toxicity profile. Therefore, sequencing of two-drug therapies instead of three-drug combinations may be preferred in frail patients. Based on the recently obtained encouraging results of CD38 mAb-based combination therapies, it is expected that mAb therapy will become first choice for the treatment of relapsed MM.

Targeted therapies, such as treatment with the BRAF inhibitor vemurafenib in BRAF-mutated MM patients or BCL-2 inhibition with venetoclax for MM with t(4;14), are currently emerging in RRMM. However, personalized therapy with targeted agents is not yet standard clinical practice. Ongoing innovative randomized and controlled clinical trials are needed to explore and validate predictive biomarkers to guide selection of therapy and to evaluate the efficacy of new promising therapies. Due to the very heterogeneous genetic landscape in MM, the sub-clonality, and the interconnection of signaling pathways, it is expected that combinatorial strategies are needed to achieve durable responses. Rationally designed combination therapies targeting MM cells in the context of their bone marrow micro-environment will induce long-term remissions and might eventually pursue cure of a subset of MM patients by preventing genomic evolution and disease progression. These combinatorial strategies are expected to include monoclonal antibodies, immune checkpoint inhibitors, vaccines, and CAR-T cells as a new treatment paradigm in RRMM in the near future. The final goal should be to find a balance among efficacy, toxicity, and cost, and to finally achieve long-lasting control of the disease and eventually even cure in a subset of patients.
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